Human TNFSF15 Virus-Like Particles

TNFSF15 (tumor necrosis factor superfamily member 15), also known as TL1A (tumor necrosis factor-like ligand 1A), is a cytokine belonging to the tumor necrosis factor (TNF) superfamily. It plays a crucial role in regulating immune responses, particularly in inflammatory and autoimmune diseases. TNFSF15 binds to its receptors, DR3 (death receptor 3) and DcR3 (decoy receptor 3), triggering downstream signaling pathways that regulate T cell activation, proliferation, and cytokine production. Studies have linked TNFSF15 to multiple pathological conditions, including rheumatoid arthritis, inflammatory bowel disease (IBD), and cancer. Due to its immunomodulatory functions, TNFSF15 has attracted significant attention in the development of biologics and vaccines to modulate immune responses in autoimmune and inflammatory diseases.

Human TNFSF15 virus-like particles (VLPs) are innovative biomimetic nanoparticles designed to deliver TNFSF15 in a highly immunogenic and structurally stable form. VLPs are non-infectious, self-assembling protein structures that resemble natural viruses in morphology but lack viral genetic material, making them safe for therapeutic and vaccine applications. By incorporating TNFSF15 into VLPs, researchers can enhance its immunogenicity and prolong its circulation time, thereby improving its therapeutic efficacy. These VLPs can be engineered to present TNFSF15 in a multivalent manner, thereby enhancing receptor binding and immune activation. Potential applications include targeted immunotherapy for autoimmune diseases, cancer treatment, and as vaccine adjuvants to enhance immune responses. Furthermore, compared to traditional cytokine therapies, TNFSF15 VLPs offer advantages such as biocompatibility, controlled release, and reduced off-target effects.